Aisling Capital Management’s BridgeBio Pharma BBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $262M | Hold |
6,068,125
| – | – | 72.85% | 1 |
|
|
2025
Q1 | $210M | Hold |
6,068,125
| – | – | 72.72% | 1 |
|
|
2024
Q4 | $167M | Hold |
6,068,125
| – | – | 59.08% | 1 |
|
|
2024
Q3 | $154M | Hold |
6,068,125
| – | – | 59.18% | 1 |
|
|
2024
Q2 | $154M | Hold |
6,068,125
| – | – | 66.52% | 1 |
|
|
2024
Q1 | $188M | Hold |
6,068,125
| – | – | 63.5% | 1 |
|
|
2023
Q4 | $245M | Hold |
6,068,125
| – | – | 73.07% | 1 |
|
|
2023
Q3 | $160M | Hold |
6,068,125
| – | – | 65.94% | 1 |
|
|
2023
Q2 | $104M | Hold |
6,068,125
| – | – | 51.13% | 1 |
|
|
2023
Q1 | $101M | Hold |
6,068,125
| – | – | 48.41% | 1 |
|
|
2022
Q4 | $46.2M | Hold |
6,068,125
| – | – | 30.53% | 1 |
|
|
2022
Q3 | $60.3M | Hold |
6,068,125
| – | – | 40.05% | 1 |
|
|
2022
Q2 | $55.1M | Hold |
6,068,125
| – | – | 39.31% | 1 |
|
|
2022
Q1 | $61.6M | Hold |
6,068,125
| – | – | 33.24% | 1 |
|
|
2021
Q4 | $101M | Hold |
6,068,125
| – | – | 35.71% | 1 |
|
|
2021
Q3 | $284M | Hold |
6,068,125
| – | – | 56.71% | 1 |
|
|
2021
Q2 | $370M | Hold |
6,068,125
| – | – | 59.23% | 1 |
|
|
2021
Q1 | $374M | Buy |
6,068,125
+2,078,713
| +52% | +$128M | 67.28% | 1 |
|
|
2020
Q4 | $284M | Hold |
3,989,412
| – | – | 48.72% | 1 |
|
|
2020
Q3 | $150M | Hold |
3,989,412
| – | – | 47.82% | 1 |
|
|
2020
Q2 | $130M | Hold |
3,989,412
| – | – | 49.65% | 1 |
|
|
2020
Q1 | $116M | Buy |
3,989,412
+153,690
| +4% | +$4.46M | 50.4% | 1 |
|
|
2019
Q4 | $134M | Hold |
3,835,722
| – | – | 51.51% | 1 |
|
|
2019
Q3 | $82.4M | Hold |
3,835,722
| – | – | 42.93% | 1 |
|
|
2019
Q2 | $103M | Buy |
+3,835,722
| New | +$103M | 44.18% | 1 |
|